The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Voxzogo label, and added the Drugs@FDA approval record. 12
What this version reported
A 52-week randomized, placebo-controlled trial in 121 children described in the label found faster annual growth than with placebo. Continued approval may depend on confirmatory trials of clinical benefit.↗
Reader guide in this version
Key takeaway
Vosoritide is a lab-made analogue of C-type natriuretic peptide (CNP), a natural regulator of bone growth, and is the active ingredient in BioMarin’s Voxzogo.1,2 It is FDA-approved under accelerated approval to increase linear growth in children with achondroplasia, a genetic condition that slows bone growth, whose growth plates are still open.1 The approval rests on growth rate: in a 52-week randomized trial of 121 children, growth was 1.57 cm per year faster with vosoritide than with placebo. The label states that continued approval may depend on a confirmatory trial.1
At a glance
- What it is
- A CNP analogue. The label states that it binds natriuretic peptide receptor-B and counteracts the overactive FGFR3 signalling that slows bone growth in achondroplasia.1
- FDA status
- FDA-approved. Voxzogo has accelerated approval, and Drugs@FDA lists it with an original approval date of November 19, 2021. The cited label has no boxed warning.1,2
- Human evidence
- A 52-week randomized, double-blind, placebo-controlled Phase 3 trial in 121 children aged 5 to 14 and a placebo-controlled study in younger children, described in the label.1
- Evidence strength
- Smaller controlled human trials
What is vosoritide?
Vosoritide is a lab-made analogue of C-type natriuretic peptide (CNP), a peptide the body uses to regulate bone growth.1
In the United States it is the active ingredient of Voxzogo, from BioMarin, according to Drugs@FDA.2
How does vosoritide work?
The label explains that in achondroplasia a gene change makes the FGFR3 receptor overactive, which slows growth at the growth plates. Vosoritide binds natriuretic peptide receptor-B and blocks part of the FGFR3 signalling pathway.1
The label states that, like CNP, it promotes the growth and maturation of cartilage cells in the growth plate. In mouse models it partly or fully corrected the short-limbed growth pattern.1
What do human studies show?
The label describes a 52-week randomized, double-blind, placebo-controlled trial in 121 children aged 5 to 14 with genetically confirmed achondroplasia, 60 of whom received vosoritide and 61 placebo.1
After 52 weeks, annualized growth velocity was 1.57 cm per year greater with vosoritide than with placebo, and the improvement was consistent across the subgroups analyzed, according to the label.1
The label also describes a 52-week placebo-controlled study in 64 children younger than 5. Growth rate is an intermediate measure and does not by itself show final adult height or function.1
What the evidence base contains
- Controlled human trial Study 1 (NCT03197766): a 52-week randomized, double-blind, placebo-controlled Phase 3 trial in 121 children aged 5 to 14 with genetically confirmed achondroplasia, with annualized growth velocity as the main outcome.1
- Controlled human trial Study 2: a 52-week randomized, double-blind, placebo-controlled study in 64 children younger than 5 with achondroplasia, described in the label’s safety section.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is vosoritide FDA-approved?
Yes, under accelerated approval. Drugs@FDA lists Voxzogo, application NDA214938, with an original approval date of November 19, 2021.2
The Voxzogo label cited here (DailyMed SPL version 16, published November 26, 2025) states that it is indicated to increase linear growth in children with achondroplasia with open growth plates, and that this indication is approved under accelerated approval based on an improvement in annualized growth velocity.1
The label states that continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.1
The label has no boxed warning and lists no contraindications. Its warning covers temporary decreases in blood pressure seen in clinical studies, which excluded children with significant heart or blood-vessel disease.1
What is still unknown?
Whether faster growth leads to greater final adult height or better function, which the label says depends on confirmatory trials.1
Its effects after the growth plates close: the label covers only children whose growth plates are open.1
Sources for this version
- 1VOXZOGO (vosoritide) kit · SPL version 16 · published 2025-11-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA214938 · original submission status AP · 2021-11-19 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026